From the point of view of the "Parkinson's laws", the state of the Russian Academy of Sciences sounds like a verdict: "Nothing can be done at the third stage. The institution has practically died. It can be updated only by moving to a new location, changing the name and all employees."
27.05.2009According to the General director of Biocad, D.Morozov, the development of the domestic pharmaceutical industry is hindered by the "stagnant" mentality of scientists and the vulnerability of domestic companies to Western pharmaceutical giants that have occupied the Russian market.
12.05.2009The pharmaceutical industry today is one of the most innovative and capacious industries. And it is in this industry that it is most difficult to establish an innovation process. Please note that only highly developed countries can afford their own innovative pharmaceutical industry. And if they managed to establish an innovation process in this segment of the economy, then in other segments it usually also succeeds.
29.04.2009In the field of science and innovation in Russia, depressing stagnation has been observed for decades. Periodically there are attempts to understand the reasons for such a failure, but they are closed, fragmentary and do not have a sufficient factual basis due to the fragmentation of the expert community itself. The report "Innovative development – the basis of modernization of the Russian economy" was published recently.
21.04.2009Interview with the Investment Director of the Russian Venture Company Yan Ryazantsev.
17.04.2009The variant of the procedure for transferring rights to the results of scientific and technical activities to development organizations, proposed by the Ministry of Finance, imposed such encumbrances on those who would like to get ownership of the rights to the results of scientific and technical activities, which is "easier to shoot yourself." And the fact that the assignment of rights to performers has been declared does not mean anything yet.
15.04.2009In the field of biosensors, the Laboratory of Electrochemical Methods of Moscow State University occupies a leading position at the world level. These devices are significantly superior in their capabilities to foreign analogues, and they can be used almost everywhere: from medicine to industrial ecology. But cheap, simple and selective analyses that can be carried out using biosensors are still underestimated in Russia.
15.04.2009The pharmaceutical industry is one of the few growing during the crisis. Currently, recruitment is mainly conducted by Western companies, especially the need for personnel is experienced by fast-growing and promising areas, such as biotechnology and the generic market. Marketers, sellers and registrars of new drugs are required there.
15.04.2009The Russian biotechnological innovation company "Eurogen" sells its technologies and products all over the world. Lukyanov is convinced that his company, armed with modern devices, would have a real chance to make a revolution in biomedicine and take a leading position in the development of new approaches to the treatment of oncological and autoimmune diseases. He knows other companies that could "jerk" if not for financial constraints.
13.04.2009The analysis was carried out only in those areas of life sciences, the results of which have a pronounced applied value: bioinformatic, biocatalytic, biosynthetic and biosensory technologies, biomedical and veterinary technologies for life support and protection of humans and animals, genomic and postgenomic technologies for the creation of medicines, cellular technologies, bioengineering technologies, technologies for the creation of biocompatible materials.
09.04.2009In order for Russians to be able to buy domestic generic drugs in pharmacies that are not inferior to imported analogues, the Russian pharmaceutical industry needs modern equipment and qualified personnel. If you translate this phrase into the language of economics, then by and large, nothing but huge investments are needed for domestic pharma. Moreover, money will have to be invested not only directly in the pharmaceutical industry, but also in science and education.
02.04.2009The state corporation announced the cooperation between Rusnano and the government of St. Petersburg in December 2008. The corresponding agreement was signed by the General Director of Rusnano Anatoly Chubais and the Governor of St. Petersburg Valentina Matvienko. The cooperation provides for joint work on the implementation of state policy in the field of nanotechnology, the creation of conditions for the commercial use of the results of developments, as well as the implementation of investment and infrastructure projects and educational programs in the field of nanoindustry
01.04.2009Chubais' goal is to create a nanomarket, to make the process of industry development "irreversible", when, without the participation of the state corporation, Russian business will generate demand and supply for nanotechnology and related products. Another benchmark is the volume of nanotechnology exports, which should grow to 180 billion rubles in 2015. In order to achieve these goals, the work of Rusnano will undergo significant changes starting in the fall of 2009.
30.03.2009The Russian nanotechnology market is at the initial stage of its formation. At the moment, Russia's share in the global technology sector is about 0.3%, and in the nanotechnology market – 0.04%. However, the authors of the report assure that Russia's lag in the nanotechnology sector is not insurmountable…
30.03.2009The crisis gives a few Russian developers of innovative pharmaceuticals a chance to attract the attention of Big Pharma and expand their market share.
27.03.2009On the basis of peptides, scientists create neuroprotective drugs that successfully combat the most severe disorders of the nervous system – neurasthenia, stroke, leading to the death of brain neurons and, as a consequence, paralysis and paresis.
23.03.2009Advanced domestic pharmaceutical manufacturers, having invested considerable sums in R& D and in the modernization of production, began to produce analogues of imported drugs, but local pharmaceutical manufacturers cannot "break through" with their products into public procurement.
17.03.2009One of the foundations of the "knowledge economy", based not on production, but on the sale of know-how, is the rapid turnover of knowledge. However, it is not clear how quickly knowledge is ready to "turn around". We will consider this question on a concrete example of the introduction of one of the achievements of fundamental science into life.
13.03.2009Germany spends 2.5% of GDP on science (EU countries average 1.8%). According to the German Ministry of Education and Research, even with an eye to the crisis, scientific research in most areas will not be curtailed, and budget funding will not be cut. It is even possible to provide additional financing for the implementation of new technologies.
12.03.2009Russia ranks 35th in the final innovation rating (the sum of points is 35.1). A higher result – the 8th position (15.2 points) – on the dynamics of innovative changes.
02.03.2009
You can write to the editor at:
vm@vechnayamolodost.ruThe editors of Eternal Youth are preparing a useful and interesting mailing list. You can get it if you leave your mail.